Zealand Pharma A/S holds the cleaner structural position, with valuation as the main driver and profitability adding further support. Alnylam Pharmaceuticals still has the edge on stability, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.
The comparison is based on similar long-term financial trajectories, not sector labels.
The clearest score difference appears in valuation. Zealand Pharma A/S leads by 28 points on the overall comparison score.
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. ALNY and ZEAL.CO share the same industry classification.
For a similarity-based comparison, see how Alnylam Pharmaceuticals and Zealand Pharma A/S each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
The two profiles are relatively close, but the price setup still leans toward Zealand Pharma A/S.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
The multiple-based pricing edge comes from a trailing P/E that is 133 turns lower.
Alnylam Pharmaceuticals, Inc. still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.
Valuation is the clearest driver of the lead, with profitability adding further support — though stability still provides a real counterweight.
Break down the ALNY vs ZEAL.CO comparison across all dimensions with the full interactive tool.
Explore how ALNY and ZEAL.CO each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.